Patents by Inventor THOMAS K. KARAMI

THOMAS K. KARAMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORM OF CYCLOSPORIN A, METHODS OF PREPARATION, AND METHODS FOR USE THEREOF
    Publication number: 20210269484
    Abstract: The present invention relates generally to crystalline forms of cyclosporin A and particularly to a newly identified form of cyclosporin A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.
    Type: Application
    Filed: January 13, 2021
    Publication date: September 2, 2021
    Inventors: Anuradha V. Gore, Thomas K. Karami, Ke Wu, Richard S. Graham, Scott W. Smith
  • Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
    Patent number: 10273206
    Abstract: The present invention provides tromethamine salt of (Z)-7-[3,5-Dihydroxy-2-((E)-3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline Form 1 and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: April 30, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Thomas K. Karami, Scott W. Smith, Fiona Dubas-Fisher, Adrian St. Clair Brown
  • Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
    Patent number: 9855232
    Abstract: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: January 2, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Ke Wu, Shaoxin Feng, Thomas K. Karami, Scott W. Smith
  • Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof
    Patent number: 9447014
    Abstract: The present invention provides tromethamine salt of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 20, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Thomas K. Karami, Scott W. Smith, Fiona Dubas-Fisher, Adrian St. Clair Brown
  • CRYSTALLINE FORMS OF BIMATOPROST ACID, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF
    Publication number: 20160175269
    Abstract: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.
    Type: Application
    Filed: July 17, 2015
    Publication date: June 23, 2016
    Inventors: Ke Wu, Shaoxin Feng, Thomas K. Karami, Scott W. Smith
  • CRYSTALLINE FORM OF CYCLOSPORIN A, METHODS OF PREPARATION, AND METHODS FOR USE THEREOF
    Publication number: 20160083432
    Abstract: The present invention relates generally to crystalline forms of cyclosporin A and particularly to a newly identified form of cyclosporin A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.
    Type: Application
    Filed: December 7, 2015
    Publication date: March 24, 2016
    Inventors: Anuradha V. Gore, Thomas K. Karami, Ke Wu, Richard S. Graham, Scott W. Smith
  • TROMETHAMINE SALT OF BIMATOPROST ACID IN CRYSTALLINE FORM 1, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF
    Publication number: 20150376125
    Abstract: The present invention provides tromethamine salt of (Z)-7-[3,5-Dihydroxy-2-((E)-3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline Form 1 and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 31, 2015
    Inventors: Thomas K. Karami, Scott W. Smith, Fiona Dubas-Fisher, Adrian St.Clair Brown
  • Crystalline form of cyclosporine A, methods of preparation, and methods for use thereof
    Patent number: 9206228
    Abstract: The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 8, 2015
    Assignee: Allergan, Inc.
    Inventors: Anuradha V. Gore, Thomas K. Karami, Ke Wu, Richard S. Graham, Scott W. Smith
  • 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]--ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
    Patent number: 9181176
    Abstract: The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: November 10, 2015
    Assignee: Allergan, Inc.
    Inventors: Gyorgy F. Ambrus, Thomas K. Karami, Ke Wu
  • Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
    Patent number: 9120738
    Abstract: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 1, 2015
    Assignee: Allergan, Inc.
    Inventors: Ke Wu, Shaoxin Feng, Thomas K. Karami, Scott W. Smith
  • CRYSTALLINE FORM OF CYCLOSPORINE A, METHODS OF PREPARATION, AND METHODS FOR USE THEREOF
    Publication number: 20140315827
    Abstract: The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: Anuradha V. Gore, Thomas K. Karami, Ke Wu, Richard S. Graham, Scott W. Smith
  • CRYSTALLINE FORMS OF BIMATOPROST ACID, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF
    Publication number: 20140187636
    Abstract: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 3, 2014
    Applicant: ALLERGAN, INC.
    Inventors: KE WU, SHAOXIN FENG, THOMAS K. KARAMI, SCOTT W. SMITH
  • TROMETHAMINE SALT OF BIMATOPROST ACID IN CRYSTALLINE FORM, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF
    Publication number: 20140187637
    Abstract: The present invention provides tromethamine salt of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 3, 2014
    Applicant: ALLERGAN, INC.
    Inventors: Thomas K. KARAMI, Scott W. SMITH, Fiona DUBAS-FISHER, Adrian ST.CLAIR